BGPT: Author Review: Alawi Alsheikh-Ali

Fuel Your Discoveries

Quick Explanation Copied

Author scientific snapshot (A. Alsheikh-Ali)

The author’s profile (h-index ~46, >8k citations in OpenAlex) is consistent with broad, high-impact cardiology work, including registry-based observational analyses and methodological/clinical reviews. Evidence-quality varies by study type; observational registry findings are hypothesis-generating and can be limited by residual confounding and selection effects.

Two example, data-grounded works show: (1) high burden of uncontrolled cardiometabolic risk factors among Middle Eastern outpatients despite widespread guideline therapies , and (2) physician-perceived barriers to shared decision-making in a Dubai private network (small cross-sectional sample; social desirability/response bias risk). .

If you want, I can compute additional effect-size summaries from the full texts if you upload PDFs or provide extraction tables.

Long Explanation

Author Review — Alawi Alsheikh-Ali

This review is constrained to verifiable information provided in your prompt: citation metrics and two paper-level, data-extract records. I therefore focus on study design, evidentiary strength, limitations, and what would change conclusions.

1) Evidence footprint (metrics provided)

OpenAlex-matching identity: Alawi Alsheikh‐Ali (ORCID: 0000-0002-1213-4546) with works_count ≈ 343, cited_by_count ≈ 8317, h-index ≈ 46.

Critical note: citation metrics are not proof of scientific truth. They can reflect field size, co-authorship patterns, and citation practices.

2) Data-grounded example #1 — REACH registry (cardiovascular risk-factor control gaps)

What the study contributes (known from the provided extraction):

Observational, prospective international registry secondary analysis of Middle Eastern outpatients with established cardiovascular disease or high risk (n=840 across Israel, Lebanon, Saudi Arabia, UAE; median age 67.6; 71.6% male).
Care gap signal: 75.6% had ≥1 uncontrolled risk factor; for the “risk-factor-only” group, 96.1% had at least one uncontrolled risk factor, despite common treatment use (e.g., statins 85.2%, antiplatelets 90.7%).

Scientific strength: The contribution is primarily descriptive/epidemiologic and is well-suited to identify where risk control is failing. However, observational registries cannot fully establish causality (e.g., uncontrolled risk factors may reflect adherence, timing, measurement differences, or under-treatment not captured by the proxy treatment-gap definition).

Limitations & skeptical checks (explicit in extraction):

Regional focus on four Middle Eastern countries and participating centers limits external validity.
Funding/industry relationships are disclosed: e.g., Sanofi-Aventis involvement (Middle East sponsorship) and author disclosures in the provided extraction.

What could disprove or materially change the interpretation? The extraction proposes a falsification direction: if in comparable populations, guideline-directed management reduces the proportion with ≥1 uncontrolled risk factor and changes 1-year outcomes, then the “persistent care gap” interpretation would be weakened.

3) Data-grounded example #2 — physician perceptions of shared decision-making (SDM)

What the study contributes (known from extraction):

Cross-sectional survey in Dubai’s private healthcare network (n=50 physicians), using SDM-Q-9 and thematic analysis; response rate reported as 85%.
Physicians rated themselves highly on SDM (80%), but thematic barriers were categorized as physician-, patient-, contextual/environmental-, and relational-related; reported as no significant differences by gender/age/experience/specialty/facility type (per extraction).

Scientific strength: For its purpose (attitudes/perceptions), the SDM-Q-9 structure plus thematic coding provides triangulation. But its evidence for “effectiveness” of SDM is indirect because it measures perceptions, not patient outcomes.

Limitations & bias risks (explicit in extraction):

Small, single-network sample and cross-sectional design limit causal inference and external validity.
Lack of patient perspective in the provided extraction constrains the completeness of the “barrier” model.

4) Integrative critique: what this suggests (and what it does not)

Most supported inference from your provided papers: The author appears to contribute substantially to clinical epidemiology and registry interpretation, where the scientific “win condition” is accurate population-level measurement and careful discussion of confounding/limitations.

Key uncertainty: From only two extracted works, I cannot responsibly generalize about the author’s rigor across all 300+ publications—especially across different methods (RCTs vs registries vs mechanistic vs computational).

Bias and reproducibility audit (what you should look for in any specific paper):

Industry/funder involvement disclosure and how it maps to outcomes and analyses (risk of sponsor bias).
Observational confounding and selection bias: who gets into registries, and how treatment gaps are defined/measured.
Measurement validity for perception surveys and social desirability risk.

5) Suggested next steps (to make this review more decisive)

Upload 3–5 full-text PDFs of Alsheikh-Ali papers spanning different designs (e.g., at least one registry, one RCT/meta-analysis, one mechanistic/omics). I can then extract: sample size, endpoints, covariate adjustment, missingness handling, statistical model specification, and whether data/code is available.
Provide or paste any “results tables” for the included papers if you want effect-size plots (e.g., adjusted odds ratios) rather than prevalences.

Feedback:

Updated: April 03, 2026